Description: Kamada Ltd., a biopharmaceutical company, develops, produces, and markets therapeutics based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases; Heparin Lock Flush to maintain potency of intravenous injection device; Kamacaine 0.5%, a spinal and epidural anesthesia; and Albumin for therapeutic plasma exchange and hypovolemic shock. In addition, the company offers Factor IX for treatment of bleeding episodes and to maintain plasma factor IX levels; Factor VIII, VWF for the treatment of bleeding episodes to maintain plasma factor VIII level, vonwillebrand disease; and Human Transferrin for in vitro and diagnostic use. Its development stage products include Aerosolized AAT, which is in Phases II-III clinical trials for alpha-1 antitrypsin deficiency, and under Phase II clinical trial for bronchiectasis, as well as completed Phase II clinical trial for cystic fibrosis; Human Transferrin for pharmaceutical use; and snake antiserum for snake bites. The company has a collaboration partnership with PARI for the development of an aerosolized AAT treatment. Kamada Ltd. sells its products through distributors worldwide, as well as is involved in marketing of imported complementing products in Israel. The company was founded in 1990 and is headquartered in Ness Ziona, Israel.
Home Page: www.kamada.com
KMDA Technical Analysis
2 Holzman Street
Rehovot,
7670402
Israel
Phone:
972 8 940 6472
Officers
| Name | Title |
|---|---|
| Mr. Amir London | Chief Exec. Officer |
| Mr. Chaime Orlev | Chief Financial Officer |
| Mr. Eran Nir | Chief Operating Officer |
| Ms. Yifat Philip Esq. | VP of Legal, Gen. Counsel & Corp. Sec. |
| Mr. David Tsur | Co-Founder & Deputy Chairman |
| Ms. Hanni Neheman | VP of Marketing & Sales |
| Ms. Ariella Raban | VP of HR |
| Mr. Jon R. Knight | VP of US Commercial Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 10.3306 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1242 |
| Price-to-Sales TTM: | 1.5766 |
| IPO Date: | 2013-05-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 355 |